Does Use of Topical Lidocaine in EGD Reduce Amount of IV Midazolam and Fentanyl Required and Shorten Recovery Time
Does Topical Lidocaine Reduce The Amount of Intravenous Conscious Sedation Required To Complete Diagnostic Upper Endoscopy and Shorten Recovery Time? A Double Blinded, Randomized, Placebo Controlled Study.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The study will be a double blinded randomized placebo controlled trial
Patients between 18 and 89 years old who are scheduled for EGD may be eligible to enroll in the study. Potential subjects will be sought through referral by their treating attending and fellow gastroenterologist, who will be apprised of the inclusion and exclusion criteria. Patients possibly meeting inclusive and exclusive criteria will be approached and discussed the study further with the investigators. Those expressing a desire to participate in the study will be given written informed consent prior to participation. The investigators will enroll patients into the study with a goal of at least 53 patients in each group which is the number of patients our statistician recommended to appropriately power our study.
Patients who consent to enroll in the study will be randomized into 2 groups. Group 1: Swish and swallow 10ml of 2% lidocaine solution Group 2: Swish and swallow 10ml of 0.45% sodium chloride solution
The patients will then undergo endoscopy for the indication identified in their clinic appointment. Following the procedure, patients will be taken to the recovery area and recovered per clinic protocol. The endoscopist will complete a satisfaction questionnaire. The day following the procedure a nurse will call to check for post-operative complications per clinic protocol. The day following, an investigator will also call to perform a patient satisfaction survey..
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Adam M Tritsch, MD
- Phone Number: 210-916-4367
- Email: adam.m.tritsch.mil@mail.mil
Study Locations
-
-
Texas
-
Ft. Sam Houston, Texas, United States, 78219
- Recruiting
- Brooke Army Medical Center
-
Contact:
- Adam M Tritsch, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- EGD alone performed by staff gastroenterologist as an outpatient
- Between the age of 18 and 89
- Not requiring anesthesia support or use of medications other than fentanyl and midazolam
Exclusion Criteria:
- Prior history of head and neck surgery
- Known hypersensitivity to local anesthetics, the amide type or any components of the topical lidocaine
- Patients having interventions other than polypectomy performed
- Pregnant or breast feeding females
- Patients with severe liver impairment
- Known hypersensitivity to benzodiazepine or fentanyl
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Patients will receive 10cc of 1/2 normal saline to gargle prior to EGD
|
0.45% Normal Saline
|
|
Experimental: Experimental
Patients will receive 10cc of 2% topical lidocaine to gargle prior to EGD
|
topical lidocaine
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Amount of sedation used
Time Frame: 60 minutes
|
We will record the amount of sedation used during the procedure
|
60 minutes
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recovery time
Time Frame: 120 minutes
|
We will record the amount of time it takes to recover following the procedure
|
120 minutes
|
|
Patient and physician satisfaction
Time Frame: 24 hours
|
We will assess patient and physician satisfaction with the procedure through use of a questionaire
|
24 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Adam M Tritsch, MD, Brooke Army Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Signs and Symptoms, Digestive
- Abdominal Pain
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Membrane Transport Modulators
- Anesthetics, Local
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Lidocaine
Other Study ID Numbers
Other Study ID Numbers
- BrookeAMC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Abdominal Pain
-
NCT07164651Active, not recruitingPediatric Abdominal Pain
-
NCT02075437CompletedFunctional Abdominal Pain
-
NCT00327548CompletedFunctional Abdominal Pain
-
NCT02565355CompletedFunctional Gastrointestinal Disorders | Functional Abdominal Pain Syndrome | Abdominal Pain (AP)
-
NCT02920268CompletedFunctional Abdominal Pain | IBS
-
NCT05892055WithdrawnFunctional Abdominal Pain Syndrome
-
NCT01675050Terminated
-
NCT00876291CompletedFunctional Abdominal Pain
-
NCT00010933Completed
Clinical Trials on Placebo
-
NCT03827590UnknownAcute Bronchitis | Acute Upper Respiratory Tract Infection
-
NCT02177513Completed
-
NCT02935712CompletedMale Subjects With Type II Diabetes (T2DM)
-
NCT06767540Not yet recruiting
-
NCT03198624CompletedPharmacokinetics | Safety Issues
-
NCT02982187CompletedPulmonary Disease, Chronic Obstructive
-
NCT04693039Completed
-
NCT01610388Completed
-
NCT04388215UnknownHypertension | Dyslipidemias